Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
Phase:
PHASE1
Details
Lead Sponsor:
Children's Mercy Hospital Kansas City
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) University of Pittsburgh